Product Description
MW-11 is being developed by Mabwell (Shanghai) Bioscience for the treatment of patients with advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04478461?term=MW-11&draw=2&rank=1)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mabwell Therapeutics
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2100050407 |
ChiCTR2100050407 | N/A |
Not yet recruiting |
Breast Cancer |
2023-09-30 |
|||
NCT04478461 |
MW11-2019-CP101 | P1 |
Unknown status |
Oncology Solid Tumor Unspecified |
2023-01-05 |
50% |
2023-02-04 |
Primary Endpoints|Treatments|Trial Status |
CTR20201239 |
CTR20201239 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-08-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |